International Commission on the Clinical Use of Human Germline Genome Editing

International Commission on the Clinical Use of Human Germline Genome Editing
Name	International Commission on the Clinical Use of Human Germline Genome Editing
Formation	2019
Purpose	To develop a framework for the potential clinical use of heritable human genome editing
Parent organization	National Academy of Medicine, National Academy of Sciences, and The Royal Society

International Commission on the Clinical Use of Human Germline Genome Editing is a global expert body convened to address the complex scientific, ethical, and governance questions surrounding the potential clinical application of heritable human genome editing. It was established in the wake of the controversial He Jiankui affair, which highlighted the urgent need for international consensus and stringent oversight. The commission's work aimed to delineate a responsible pathway forward, should society ever deem such interventions permissible, by synthesizing evidence from genetics, embryology, and bioethics.

Background and formation

The commission was formed in 2019 as a direct response to the international outcry following the announcement by He Jiankui that he had created the world's first genome-edited babies using CRISPR-Cas9. This event was widely condemned by the global scientific community, including organizations like the World Health Organization and the International Society for Stem Cell Research. The founding bodies—the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the U.K. Royal Society—jointly launched the initiative to restore public trust and establish clear guardrails. Its creation was also informed by prior foundational reports, such as those from the International Summit on Human Gene Editing and the Nuffield Council on Bioethics.

Mandate and scope

The commission's primary mandate was to develop a technical framework detailing the scientific and clinical requirements that would need to be met before any clinical use of heritable human genome editing could be considered. Its scope was deliberately focused on the "clinical use" of the technology, rather than broader philosophical debates about its ultimate acceptability. The work was intended to complement parallel efforts by other bodies, such as the WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. The commission examined specific potential applications, initially limiting its analysis to preventing serious monogenic disorders where no reasonable alternatives exist.

Key recommendations and findings

In its seminal 2020 report, the commission concluded that heritable human genome editing was not yet ready for clinical application, citing unresolved issues regarding safety, efficacy, and long-term monitoring. It recommended a stringent, stepwise pathway beginning with a limited set of conditions, such as Huntington's disease or cystic fibrosis, where the genetic cause is unequivocal. The report emphasized the necessity of comprehensive preclinical research in human embryos and stringent oversight by a dedicated international body. It also called for the establishment of a global registry for all research involving human germline editing to ensure transparency and accountability.

Membership and governance

The commission comprised a multidisciplinary group of twenty-one leading experts from twelve countries, co-chaired by Margaret A. Hamburg, former commissioner of the U.S. Food and Drug Administration, and Dame Kay Davies, a renowned geneticist from the University of Oxford. Members included specialists in assisted reproductive technology like Richard H. Reindollar, ethicists such as Françoise Baylis from Dalhousie University, and scientists like J. Keith Joung from Massachusetts General Hospital. The governance and secretariat functions were provided by the staff of the National Academies of Sciences, Engineering, and Medicine in Washington, D.C..

International response and impact

The commission's report was received as a critical and authoritative contribution to the global discourse, informing the policies of numerous national academies and regulatory agencies. Its recommendations directly influenced the subsequent framework published by the World Health Organization and were cited in position statements by the European Society of Human Genetics and the Hinxton Group. While some advocacy groups like the Center for Genetics and Society argued its recommendations did not go far enough toward a permanent moratorium, the report was largely praised for its technical rigor and cautious approach by journals like *Nature* and *Science*.

Ethical and regulatory considerations

The commission's work was deeply interwoven with profound ethical and regulatory questions, engaging with principles articulated in documents like the UNESCO Universal Declaration on the Human Genome and Human Rights. It grappled with issues of international justice, potential eugenic misuse, and the welfare of future generations. The report argued that any potential clinical pathway must operate within robust national and international governance structures, potentially involving new treaties or the strengthening of existing ones like the Oviedo Convention. It stressed that public engagement, as championed by bodies like the Wellcome Trust, was a prerequisite for any societal decision to proceed.

Category:Bioethics organizations Category:Genetics organizations Category:Medical and health organizations based in Washington, D.C.